methylphenidate hydrochloride extended-release tablets

DRUG2 trials

Sponsors

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Conditions

Attention Deficit Disorder With HyperactivityAttention Deficit Hyperactivity Disorder

Phase 3

A Safety and Effectiveness Study of Methylphenidate HCl Extended-release Tablets in Adults With Attention Deficit Hyperactivity Disorder

CompletedNCT00326391

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Attention Deficit Disorder With Hyperactivity

Start: 2006-04-30End: 2006-12-31Updated: 2011-05-24

A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity Disorder

CompletedNCT00326300

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Attention Deficit Hyperactivity Disorder

Start: 2006-04-30End: 2007-08-31Updated: 2011-05-24

Related Papers

A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy

Journal of Comparative Effectiveness Research2024-08-122 citations